Evidence map›Paper›PMID 40166436›Full record

ArticleDiabetology international2025

Impact of a COVID-19 emergency declaration on blood glucose levels in individuals with type 1 diabetes treated with a sensor-augmented pump.

Tomofumi Takayoshi, Yushi Hirota, Akane Yamamoto, Kai Yoshimura, Seiji Nishikage, Mariko Ueda, Wataru Ogawa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tomofumi TakayoshiDepartment of Internal Medicine, Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017 Japan.
Yushi HirotaDepartment of Internal Medicine, Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017 Japan.ORCID 0000-0002-3035-4155
Akane YamamotoDepartment of Internal Medicine, Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017 Japan.
Kai YoshimuraDepartment of Internal Medicine, Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017 Japan.
Seiji NishikageDepartment of Internal Medicine, Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017 Japan.
Mariko UedaDepartment of Internal Medicine, Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017 Japan.
Wataru OgawaDepartment of Internal Medicine, Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017 Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: COVID-19 emergency declarations and ensuing lockdowns affected lifestyle and glycemic control in individuals with diabetes mellitus, with some studies finding improvement and others deterioration of glucose management. The effects of such emergency declarations in Asian populations, including individuals with type 1 diabetes (T1D) managed with a sensor-augmented pump (SAP), have been unclear, however. We here investigated the impact of a COVID-19 emergency declaration on glycemic control in Japanese individuals with T1D treated with a SAP device. Methods: This retrospective investigation included individuals with T1D who were managed with SAP technology and had continuous glucose monitoring including sensor glucose levels and time above range, time in range [TIR], and time below range and insulin dose data available in electronic health records from February to July 2020, corresponding to periods before, during, and after the declared emergency. Results: The 78 enrolled individuals had a mean age of 44.6 years, diabetes duration of 15.4 years, and hemoglobin A Conclusion: Individuals with T1D treated with a SAP device showed improved glycemic management after the COVID-19 emergency declaration. Supplementary Information: The online version contains supplementary material available at 10.1007/s13340-025-00802-4.

Indexed as

COVID-19Emergency declarationsSensor-augmented pumpTime in rangeType 1 diabetes

Identifiers

PMID40166436
PMCPMC11954778

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.